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Abstract We analyzed the effects of the initial approach to
patients with follicular lymphoma (FL) on outcomes in order
to investigate whether the watch and wait (WW) strategy is still
an acceptable approach in the rituximab era. We retrospectively
analyzed 348 patients who were initially diagnosed with FL
between 2000 and 2012. We compared the clinical outcomes
of theWWcohort and immediate treatment cohort. Among 348
patients (median age of 57 years, range: 19–85), 101 were
initially managed with WWand 247 were immediately treated.
The median follow-up duration was 75 months (range: 7–169).
The estimated median time to treatment failure (TTF) in the
treatment following WW cohort and immediate treatment co-
hort were 92months (95%CI, 60.1–NA) and 77months (95%
CI, 65.1–107.6), respectively, which were not significantly dif-
ferent (P = 0.272) . In a multivariate analysis, clinical stage was
identified as a predictive factor of TTF (HR 1.19, 95 % CI,
1.03–1.38, P < 0.05). Neither overall survival rate nor cumula-
tive risk of transformation between the WW cohort and imme-
diate treatment cohort was significant. The results of the present
study suggested that the WW strategy is still an acceptable
approach for selected FL patients in the rituximab era.
Keywords Follicular lymphoma .Watch andwait . Time to
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Introduction
In the pre-rituximab era, several studies revealed that the
watch and wait (WW) strategy was not associated with the
outcomes of patients with follicular lymphoma (FL) regard-
less of their tumor burden [1–7]. These findings confirmed
that WW may be one of the standard approaches for patients
with asymptomatic FL. However, it is currently being debated
whether WW is still acceptable in the rituximab era.
In recent years, the role of WW has been examined in more
detail in patients with FL. Two retrospective studies concluded
that theWW strategy is still an acceptable approach for selected
patients [8, 9]. Another two prospective studies reported that the
outcomes of a cohort managed with WW were poorer in those
treated with rituximab-containing therapy [10, 11]. Therefore,
in the rituximab era, there are no longer adequate grounds for
the immediate treatment of patients with FL. We herein report
the results of our retrospective study on the effects of the initial
approach to patients with FL on outcomes.
Patients and methods
Patients who were newly diagnosed with FL grades 1 to 3a in
accordance with the World Health Organization classification
[12] at the National Cancer Center Hospital between 2000 and
2012 were included irrespective of age, Ann Arbor stage,
Eastern Cooperative Oncology Group performance status,
symptoms, tumor burden, Fol l icular Lymphoma
International Prognostic Index 2 (FLIPI2) [13], and time to
start the initial treatment. In the present study, a high tumor
burden (HTB) was defined as cases with at least one of the
following items: the largest mass of more than 7 cm, more
than three nodal sites with a diameter >3 cm, significant se-
rous effusion, organ compression, and symptomatic
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splenomegaly [4]. Exclusion criteria were the presence of a
histological transforming component such as diffuse large B
cell lymphoma (DLBCL) at the time of the initial diagnosis or
patients who were enrolled in new agent clinical trials. The
decision on when to start the initial treatment was made by the
responsible physicians. Patients were managed in accordance
with good practice rules. Clinical data were collected from our
medical records, including patient baseline characteristics, ini-
tial approaches, responses after the treatment, and reasons for
starting the treatment following WW. We evaluated overall
survival (OS), time to treatment failure (TTF), and the cumu-
lative risk of transformation. Judgments on transformation
were made pathologically and/or clinically. Clinical transfor-
mation was considered, for example, when the patient exhib-
ited rapid elevations in lactate dehydrogenase, rapid growth of
the tumor, B symptoms, or hypercalcemia.
We compared the outcomes of patients who were treated
followingWWwith those who were immediately treated. The
WW cohort was defined as patients who did not received the
initial treatment in the first 3 months of the diagnosis. In the
WW cohort, the clinical features of patients who needed to be
treated after observations were also analyzed.
TTF was defined as the time from the initial diagnosis to
progression or death after the first treatment regardless of the
initial approach. Patients who continued WW during the
follow-up were not included as subjects for TTF. OS was de-
fined as the time from the initial diagnosis to death by any cause
and was analyzed using the Kaplan-Meier method. In the anal-
ysis of OS, transformation was regarded as a time-dependent
covariate. Cox’s proportional hazards model was used to assess
relationships between clinical variables and treatment failure or
death. The cumulative incidence of transformation was deter-
mined by using death as a competing risk. The cumulative risk
of transformation was estimated using the Gray method. The
relationship between clinical variables and transformation was
analyzed using the Fine-Gray proportional hazards models
[14]. Fisher’s exact test was used to compare two categorical
variables. In this study, two-sided p values less than 0.05 were
considered significant. All analyses were performed with EZR
(Easy R) version 1.32 (Saitama Medical Center, Jichi Medical
University), which is a graphical user interface for R (The R
Foundation for Statistical Computing, version 3.2.2) [15].
This study was conducted according to the provisions of
the Declaration of Helsinki. The Institutional ReviewBoard of
the National Cancer Center approved this study protocol.
Results
Patient characteristics
Between January 2000 and December 2012, 348 patients,
with a median age of 57 years (range: 19–85 years), were
newly diagnosed with FL grades 1 to 3a without the compo-
nents of DLBCL in our institution. According to the physi-
cian’s discretion, 101 patients were initially managed with
WWand 247 were immediately treated.
The baseline characteristics of patients are shown in
Table 1. No patients with B symptoms were observed in the
WWcohort. Clinical physicians preferred to immediately treat
patients with histological grade 2 or 3a, FLIPI2 high, perfor-
mance status 1 or higher, or HTB.
Treatment following WW
In the WW cohort, 45 patients (45 %) received an anti-
lymphoma treatment after a median WW duration of
16 months (range: 3–122 months). The reasons for starting
this treatment after WWare listed in Table 2, with the progres-
sion of tumors being the most common reason (58%). Sixteen
patients advanced to HTB from a low tumor burden (LTB)
during WW. Treatments following WW included rituximab
plus chemotherapy in 27 patients (60%), rituximabmonother-
apy in 11 (24 %), radiotherapy alone in 4 (9%), and
chemotherapy alone in 3 (7%) (Table 3). No patients received
rituximab maintenance therapy during the study period.
Response and TTF
By the end of the follow-up, 289 patients including 42 in the
WW cohort and 247 in the immediate cohort had completed
the initial treatment. Responses to the initial treatment were as
follows: 228 patients achieved a complete response, 54 partial
responses, two stable diseases, and five progressive diseases.
Among the patients who received the initial treatment during
the follow-up, 136 were regarded as treatment failures after
the initial treatment: 15 out of 42 (36%) in theWW cohort and
121 out of 247 (49 %) in the immediate treatment cohort. The
estimated median TTF were 92 months (95 % CI, 60.1–NA)
in theWWcohort and 77months (95%CI, 65.1–107.6) in the
immediate treatment cohort, which were not significantly
different (P = 0.272) (Fig. 1). In a multivariate analysis,
clinical stage 3 or 4 was identified as a predictive factor for
TTF (HR 1.19, 95 % CI, 1.03–1.38, P < 0.05).
OS
Nineteen (6 %) patients died with a median follow-up of
75 months (range: 7–169). The causes of their deaths in-
cluded the progression of FL in 8 patients: 5 had no ev-
idence of transformation, 2 clinically transformed FL, and
1 pathologically transformed FL; secondary malignancies
in 8: 2 with acute lymphoblastic leukemia, 2 acute mye-
loid leukemia, 1 primary unknown small cell carcinoma, 1
lung cancer, and 1 esophageal cancer; idiopathic pulmo-
nary fibrosis in 1; acute heart failure of unknown etiology
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in 1; and unknown in 1. The difference in OS rates be-
tween the WW cohort and the immediate treatment cohort
was not significant (P = 0.294) (Fig. 2a). Clinical stage
(HR 2.05, 95 % CI, 1.12–3.75, P < 0.05), age >60 years
(HR 3.87, 95 % CI, 1.52–9.85, P < 0.05), and transforma-
tion (as a time-dependent covariate) (HR 6.15, 95 % CI,
1.64–23.02, P < 0.05) were identified as risk factors for
death in the multivariate analysis.
Incidence of transformation
Nineteen patients (6 %) exhibited transformation: 3 in the WW
cohort and 16 in the immediate treatment cohort. Only three
patients were proven to have pathologically transformed FL
while the remaining patients showed clinical transformation.
The median time to events was 54 months (range: 9–166).
The cumulative risk of transformation in the two cohorts was
similar (P = 0.64) (Fig. 2b). The cumulative incidence rates of
transformation at 5 and 10 years were 4.4 % (95 % CI, 1.0–
11.8) and 4.4 % (95 % CI, 1.0–11.8) in the WW cohort and
3.6 % (95 % CI, 1.7–6.7) and 7.6 % (95 % CI, 4.2–12.1) in the
immediate treatment cohort, respectively. In the multivariate
analysis, none of the baseline characteristics or initial
approaches was significant for the risk of transformation.
Subgroup analysis by tumor burden
We performed subgroup analyses of TTF, OS, and transfor-
mation rates in all patients according to their tumor burden.
The WW cohort had 20 patients with HTB and 81 with LTB,
Table 1 Patient characteristics at
the initial diagnosis WW cohort (N = 101) Immediate treatment cohort (N = 247) P
Characteristics No. % No. %
Age (years)
Median 59 57 0.07
Range 35–85 19–85
>60 45 45 % 84 34 %
Male 52 51 % 112 45 % 0.34
Performance status
0 97 96 % 193 78 % <0.001
1 4 4 % 53 21 %
2 0 0 % 1 0 %
Histological grade
1 55 54 % 90 36 % 0.004
2 35 35 % 102 41 %
3a 11 11 % 55 22 %
Ann Arbor stage
1 24 24 % 54 22 % 0.100
2 18 18 % 22 9 %
3 18 18 % 48 19 %
4 41 41 % 123 50 %
Bone marrow involvement 32 32 % 96 39 % 0.22
B symptoms 0 0 % 12 5 % 0.02
FLIPI2
Low 58 57 % 120 49 % 0.034
Intermediate 20 20 % 51 21 %
High 8 8 % 46 19 %
Unknown 15 15 % 30 12 %
High tumor burden 20 20 % 130 53 % <0.001
WW watch and wait, FLIPI Follicular Lymphoma International Prognostic Index
Table 2 Reasons for
starting the treatment
after WW (N = 45)
Reason No. %
Progression of tumors 26 58
Development of symptoms 9 20
Organ compression 4 9
Patient request 3 7
Transformation 2 4
Other 1 2
WW watch and wait
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while the immediate treatment cohort had 130 with HTB and
117 with LTB. In both subgroups, no significant differences
were observed in the TTF, OS, or transformation rates
between the two cohorts.
Discussion
This was a retrospective analysis that focused on the influence
of the WW strategy for patients with newly diagnosed FL in
the rituximab era. We analyzed the clinical outcomes of the
whole population of FL in our institution in order to identify
patients manageable with WW in the rituximab era.
In the present study, TTF, which was defined as the time
from the initial diagnosis to progression or death after the first
treatment, was considered to be one of the reasonable end-
points, while some research on FL selected progression-free
survival (PFS) for the primary endpoint, the time from start of
the initial treatment, or WW to disease progression or death.
The difference between TTF in our study and PFS was wheth-
er WW is regarded as one of the initial treatments. Since it is
not rare for FL to regrow repeatedly after responding to pre-
vious treatments, it is necessary to use TTF in order to verify
whether the WW strategy has the potential to successfully
postpone the initial treatment of FL.
In the present study, the estimated TTF in patients treated
following WW was 92 months, which appears to be better
than those reported recently. Solal-Cligny et al. retrospectively
investigated 107 patients with LTB in the F2-study database
who were initially managed with WW. The 4-year freedom
from treatment rate was 79%, which was not inferior to that of
patients with LTB who were initially treated with a rituximab-
based regimen [8]. In a randomized phase III trial conducted
by Ardeshna et al., 379 patients with LTB were randomly
assigned to the WW arm, rituximab induction arm, or rituxi-
mab induction followed by a rituximab maintenance arm.
They reported that the time to the start of the new treatment
in the WW arm was significantly shorter than the time to the
next treatment in the other two arms [10]. Although only pa-
tients with no symptoms with LTB were evaluated in their
phase III trial, we analyzed the clinical data of patients with
FL irrespective of their symptoms and tumor burden.
It has not yet been proven that the immediate treatment of
patients after the diagnosis of FL delays the incidence of trans-
formation. No significant differences were observed in the
cumulative risk of transformation between the WW cohort
and immediate treatment cohort in the present study. A
prospective observational study that mainly evaluated the in-
cidence of histological transformation of FL has been con-
ducted; 631 patients were enrolled, the transformation rate at
5 years was the highest in patients who were initially observed
without any treatments, and immunochemotherapy improved
post-transformation prognoses [11]. This observational study
did not show definitive criteria for starting treatments or how
to follow-up patients. A prospective interventional trial needs
to be conducted in order to clarify whether the WW strategy
affects the incidence of transformation of FL.
It was also essential for us to identify the best candidates for
theWW strategy. In clinical practice, physicians typically take
account of the tumor burden, which is based on the criteria
advocated by Group d’ Etude des Lymphomes Folliculaires
[4, 16], British National Lymphoma Investigation [5], and
German Low-grade Lymphoma Study Group [17].
Rituximab plus chemotherapy is regarded as the standard
treatment strategy for patients with HTB. On the other hand,
it is acceptable to observe patients with LTB without any
treatment until progression to HTB [18]. Although the WW
cohort in the present study had more patients with LTB, no
Table 3 Initial treatments
Treatment following WW (N = 45) Immediate treatment (N = 247)
Treatment No. % No. %
Rituximab monotherapy 11 24 20 8
Rituximab + chemotherapy 27 60 169 68
Chemotherapy 3 7 7 3
Radiation therapy only 4 9 35 14
Radiation + chemotherapy ± rituximab 0 0 16 6



















247 130 44 1
42 24 5 0
Number at risk
Abbreviation: WW, watch and wait. 
Fig. 1 TTF of the treatment following WW cohort and immediate
treatment cohort
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significant differences were observed in outcomes between
the WW cohort and immediate treatment cohort. This result
suggests that the WW strategy based on the tumor burden is
acceptable in the rituximab era.
There were several limitations to this study. The number
of events may not have been sufficient for evaluation in the
analysis of OS and transformation rate. There might be var-
ious reasons why the risk of transformation was lower than
we had expected: short duration of follow-up, difficulty in
detecting the data on incidence of clinical transformation,
and small number of the patients with high FLIPI2 score.
Furthermore, the results may have been affected by the phy-
sicians’ choices in assigning patients to a cohort. In addi-
tion, the restrictions associated with a retrospective study
added further obstacles.
In conclusion, the WW strategy did not have a negative
impact on TTF, OS, or transformation in selected patients with
FL. These results suggest that this strategy is still an accept-
able approach for FL patients in the rituximab era. Further
studies, particularly a prospective cohort study including an
evaluation of optimal criteria for starting anti-lymphoma
treatments, will confirm these results.
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